[
  {
    "ts": null,
    "headline": "Canaccord Genuity Reiterates a Buy on Biogen (BIIB)",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc. (NASDAQ:BIIB) and set a price target of $220.00. Biogen Inc. (NASDAQ:BIIB) reported total revenue of $2.6 billion in its fiscal Q2 2025 results, […]",
    "url": "https://finnhub.io/api/news?id=bd8827b6908b87372950b9d34840f936f7b3bec9c87b38e3808ef089bbcf65f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052699,
      "headline": "Canaccord Genuity Reiterates a Buy on Biogen (BIIB)",
      "id": 136782219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc. (NASDAQ:BIIB) and set a price target of $220.00. Biogen Inc. (NASDAQ:BIIB) reported total revenue of $2.6 billion in its fiscal Q2 2025 results, […]",
      "url": "https://finnhub.io/api/news?id=bd8827b6908b87372950b9d34840f936f7b3bec9c87b38e3808ef089bbcf65f2"
    }
  },
  {
    "ts": null,
    "headline": "Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?",
    "summary": "Biogen recently announced that the U.S. FDA has accepted its investigational new drug (IND) application for BIIB142, an IRAK4 degrader developed in partnership with C4 Therapeutics, for exploration in autoimmune diseases. This milestone highlights the growing validation of C4 Therapeutics' targeted protein degradation platform and entitles the company to a US$2 million payment once clinical dosing begins. We'll explore how the FDA acceptance of Biogen's IND application for BIIB142...",
    "url": "https://finnhub.io/api/news?id=d3056ec3a85733cdd4ffd6d9bad27ce76a33fc8f48de6cad0f734869163e6616",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024305,
      "headline": "Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?",
      "id": 136773926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen recently announced that the U.S. FDA has accepted its investigational new drug (IND) application for BIIB142, an IRAK4 degrader developed in partnership with C4 Therapeutics, for exploration in autoimmune diseases. This milestone highlights the growing validation of C4 Therapeutics' targeted protein degradation platform and entitles the company to a US$2 million payment once clinical dosing begins. We'll explore how the FDA acceptance of Biogen's IND application for BIIB142...",
      "url": "https://finnhub.io/api/news?id=d3056ec3a85733cdd4ffd6d9bad27ce76a33fc8f48de6cad0f734869163e6616"
    }
  }
]